Strategies for management and treatment of dyslipidemia in HIV/AIDS

References

• Acevedo , M. , Sprecher , D.L. , Calabrese , L. , Pearce , G.L. , Coyner , D.L. Halliburton , S.S. 2002 . Pilot study of coronary atherosclerotic risk and plaque burden in HIV patients: A call for cardiovascular prevention . Atherosclerosis , 163 : 349 – 354 .
   PubMed Web of Science ®Google Scholar
• Allan , D.A. and Behrman , A.J. 2001 . Lipid abnormalities in a healthcare worker receiving HIV prophylaxis . International Journal of STD and AIDS , 12 : 532 – 534 .
   PubMed Web of Science ®Google Scholar
• Amacher , D.E. , Beck , R. , Schomaker , S.J. and Kenny , C.V. 1997 . Hepatic microsomal enzyme induction, beta-oxidation and cell proliferation following administration of clofibrate, gemfibrozil or bezafibrate in the CD rat . Toxicology and Applied Pharmacology , 142 : 143 – 150 .
   PubMed Web of Science ®Google Scholar
• Barrios , A. , Blanco , F. , García-Benayas , T. , Gómez-Viera , J.M. , de la Cruz , J.J. Soriano , V. 2002 . Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia . AIDS , 16 : 2079 – 2081 .
   PubMed Web of Science ®Google Scholar
• Bermingham , R.P. , Whitsitt , T.B. , Smart , M.L. , Nowak , D.P. and Scalley , R.D. 2000 . Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil . American Journal of Health-System Pharmacy , 57 : 461 – 464 .
   PubMed Web of Science ®Google Scholar
• Bonnet , F. , Bonarek , M. , de Witte , S. , Beylot , J. and Morlat , P. 2002 . Efavirenz-associated severe hyperlipidemia . Clinical Infectious Diseases , 35 : 776 – 777 .
   PubMed Web of Science ®Google Scholar
• Bozzette , S.A. , Ake , C.F. , Tam , H.K. , Chang , S.W. and Louis , T.A. 2003 . Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection . New England Journal of Medicine , 348 : 702 – 710 .
   PubMed Web of Science ®Google Scholar
• Calza , L. , Manfredi , R. , Farneti , B. and Chiodo , F. 2003 . Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy . International Journal of Antimicrobial Agents , 22 : 54 – 59 .
   PubMed Web of Science ®Google Scholar
• Carr , A. , Thorisdottir , A. , Samaras , K. , Kaufmann , G.R. , Chisholm , D.J. , & Cooper , D.A. (1999) . Reversibility of protease inhibitor (PI) lipodystrophy syndrome on stopping PIs or switching to nelfinavir [abstract 668] . Available at: http://www.retroconference.org/99/abstracts/668.htm
   Google Scholar
• Currier , J. , Taylor , A. , Boyd , F. , Kawabata , H. , Maa , J. Dezii , C. 2002 . Coronary heart disease (CHD) in HIV-infected individuals: Associations with antiretroviral therapy [abstract 54] . Antiviral Therapy , 7 : L37
   PubMed Web of Science ®Google Scholar
• Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group (2003) . Combination antiretroviral therapy and the risk of myocardial infarction [erratum New England Journal of Medicine, 350, 955] . New England Journal of Medicine , 349 , 1993 – 2003 .
   PubMedGoogle Scholar
• Decker , C.J. , Laitinen , L.M. , Bridson , G.W. , Raybuck , S.A. , Tung , R.D. and Chaturvedi , P.R. 1998 . Metabolism of amprenavir in liver microsomes: Role of CYP3A4 inhibition for drug interactions . Journal of Pharmaceutical Sciences , 87 : 803 – 807 .
   PubMed Web of Science ®Google Scholar
• Doser , N. , Sudre , P. , Telenti , A. , Wietlisbach , V. , Nicod , P. Darioli , R. 2001 . Persistent dyslipidemia in HIV-infected individuals switched from a protease inhibitor-containing to an efavirenz-containing regimen . Journal of Acquired Immune Deficiency Syndrome , 26 : 389 – 390 .
   PubMed Web of Science ®Google Scholar
• Dubé , M.P. , Stein , J.H. , Aberg , J.A. , Fichtenbaum , C.J. , Gerber , J.G. , Tashima , K.T. , et al. , for the Adult AIDS Clinical Trials Group Cardiovascular Subcommittee (2003) . Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: Recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group . Clinical Infectious Diseases , 37 , 613 – 627 .
   PubMed Web of Science ®Google Scholar
• Duncombe , C. , Bloch , M. , Austin , D. , & Quan , D. (1999) . Reversal of hyperlipidaemia and lipodystrophy in patients switching therapy to nelfinavir [abstract 12287]. Bridging the Gap: 12th World AIDS Conference, Geneva, Switzerland, 29 June 1998
   Google Scholar
• Eagling , V.A. , Back , D.J. and Barry , M.G. 1997 . Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir . British Journal of Clinical Pharmacology , 44 : 190 – 194 .
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults . 2001 . Executive summary of the third report of the national cholesterol education program (NCEP) (Adult Treatment Panel III) . Journal of the American Medical Association , 285 : 2486 – 2497 .
   PubMed Web of Science ®Google Scholar
• Fichtenbaum , C.J. and Gerber , J.G. 2002a . Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection . Clinical Pharmacokinetics , 41 : 1195 – 1211 .
   PubMed Web of Science ®Google Scholar
• Fichtenbaum , C.J. , Gerber , J.G. , Rosenkranz , S.L. , Segal , Y. , Aberg , J.A. , Blaschke , T. , et al. and the NIAID AIDS Clinical Trials Group (2002b) . Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047 . AIDS , 16 , 569 – 577 .
   PubMed Web of Science ®Google Scholar
• Friis-Moller , N. , Sabin , C.A. , Weber , R. , D'Arminio , M.A. , el Sadr , W.M. Reiss , P. 2003a . Combination antiretroviral therapy and the risk of myocardial infarction . New England Journal of Medicine , 349 : 1993 – 2003 .
   PubMed Web of Science ®Google Scholar
• Friis-Moller , N. , Weber , R. , Reiss , P. , Thiebaut , R. , Kirk , O. d'Arminio , M.A. 2003b . Cardiovascular disease risk factors in HIV patients' association with antiretroviral therapy. Results from the DAD study . AIDS , 17 : 1179 – 1193 .
   PubMed Web of Science ®Google Scholar
• Garg , A. and Grundy , S.M. 1990 . Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus . Journal of the American Medical Association , 264 : 723 – 726 .
   PubMed Web of Science ®Google Scholar
• Green , M.L. 2002 . Evaluation and management of dyslipidemia in patients with HIV infection . Journal of General Internal Medicine , 17 : 797 – 810 .
   PubMed Web of Science ®Google Scholar
• Grunfeld , C. , Kotler , D.P. , Hamadeh , R. , Tierney , A. , Wang , J. and Pierson , R.N. 1989 . Hypertriglyceridemia in the acquired immunodeficiency syndrome . American Journal of Medicine , 86 : 27 – 31 .
   PubMed Web of Science ®Google Scholar
• Grunfeld , C. , Pang , M. , Doerrler , W. , Shigenaga , J.K. , Jensen , P. and Feingold , K.R. 1992 . Lipids, lipoproteins, triglyceride clearance and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome . Journal of Clinical Endocrinology and Metabolism , 74 : 1045 – 1052 .
   PubMed Web of Science ®Google Scholar
• Haas , D.W. , Zala , C. , Schradar , S. , Piliero , P. , Jaeger , H. Nunes , D. 2003 . Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: A randomized comparative pilot trial . AIDS , 17 : 1339 – 1349 .
   PubMed Web of Science ®Google Scholar
• Henry , K. , Melroe , H. , Huebesch , J. , Hermundson , J. and Simpson , J. 1998 . Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities . Lancet , 352 : 1031 – 1032 .
   PubMed Web of Science ®Google Scholar
• Holmberg , S.D. , Moorman , A.C. , Williamson , J.M. , Tong , T.C. , Ward, D.J. , Wood , K.C. , et al. & the HIV Outpatient Study (HOPS) Investigators (2002) . Protease inhibitors and cardiovascular outcomes in patients with HIV-1 . Lancet , 360 , 1747 – 1748 .
   PubMed Web of Science ®Google Scholar
• Hsyu , P.H. , Schultz-Smith , M.D. , Lillibridge , J.H. , Lewis , R.H. and Kerr , B.M. 2001 . Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin . Antimicrobial Agents and Chemotherapy , 45 : 3445 – 3450 .
   PubMed Web of Science ®Google Scholar
• Klein , D. , & Hurley , L. (2003) . Hospitalizations for coronary heart disease and myocardial infarction among men with HIV-1 infection: Additional follow-up [abstract 747] . Available at: http://www.retroconference.org/2003/Abstract/Abstract.aspx?AbstractID = 2184
   Google Scholar
• Knopp , R.H. 1999 . Drug treatment of lipid disorders . New England Journal of Medicine , 341 : 498 – 511 .
   PubMed Web of Science ®Google Scholar
• Kumar , P. , Rodriguez-French , A. , Thompson , M. , Tashima , K. , Williams , V. , Wannamaker , P. , et al. (2002) . Prospective study of hyperlipidemia in ART-naïve subjects taking combivir/abacavir (COM/ABC), COM/nelfinavir (NFV) or stavudine (d4T)/lamivudine (3TC)/NFV (ESS40002) [abstract 33] . Available at: http://www.retroconference.org/2002/Abstract/13081.htm
   Google Scholar
• Manfredi , R. and Chiodo , F. 2001 . Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: Frequency, relationship with administered drugs and role of hypolipidaemic therapy with bezafibrate . Journal of Infection , 42 : 181 – 188 .
   PubMed Web of Science ®Google Scholar
• Martínez , E. , Arnaiz , J.A. , Podzamczer , D. , Dalmau , D. , Ribera , E. , Domingo , P. , et al. for the Nevirapine, Efavirenz and Abacavir (NEFA) Study Team (2003) . Substitution of nevirapine, efavirenz or abacavir for protease inhibitors in patients with human immunodeficiency virus infection . New England Journal of Medicine , 349 , 1036 – 1046 .
   PubMed Web of Science ®Google Scholar
• Martínez , E. , Conget , I. , Lozano , L. , Casamitjana , R. and Gatell , J.M. 1999 . Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine . AIDS , 13 : 805 – 810 .
   PubMed Web of Science ®Google Scholar
• Mary-Krause , M. , Cotte , L. , Simon , A. , Partisani , M. & Costagliola , D. , & the Clinical Epidemiology Group from the French Hospital Database (2003) . Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men . AIDS , 17 , 2479 – 2486 .
   PubMed Web of Science ®Google Scholar
• Meienberg , F. , Battegay , E. , Bucher , H.C. and Battegay , M. 2001 . The use of lipid-lowering agents in HIV-infected patients . Journal of HIV Therapy , 6 : 40 – 44 .
   PubMedGoogle Scholar
• Meng , Q. , Lima , J.A. , Lai , H. , Vlahov , D. , Celentano , D.D. Strathdee , S. 2002 . Use of HIV protease inhibitors is associated with left ventricular morphologic changes and diastolic dysfunction . Journal of Acquired Immune Deficiency Syndrome , 30 : 306 – 310 .
   PubMed Web of Science ®Google Scholar
• Montaner , J.S.G. (2000) . A novel use of abacavir to simplify therapy and reduce toxicity in PI experienced patients successfully treated with HAART: 48-week results (CNA30017) [abstract 477] . 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 17–20 September . Herndon , VA : ASM Press .
   Google Scholar
• Moore , R.D. , Keruly , J.C. , & Lucas , G. (2003) . Increasing incidence of cardiovascular disease in HIV-infected persons in care [abstract 132] . Available at: http://www.retroconference.org/2003/Abstract/Abstract.aspx?AbstractID = 217
   Google Scholar
• Moyle , G.J. , Lloyd , M. , Reynolds , B. , Baldwin , C. , Mandalia , S. and Gazzard , B.G. 2001 . Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy . AIDS , 15 : 1503 – 1508 .
   PubMed Web of Science ®Google Scholar
• Murphy , R.L. and Smith , W.J. 2002 . Switch studies: A review . HIV Medicine , 3 : 146 – 155 .
   PubMedGoogle Scholar
• Murphy , R.L. , Pokrovsky , V. , Rozenbaum , W. , Wood , R. , Percival , L. , Odeshoo , L. , et al. (2003a) . Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or ATV: 108-week results of BMS Study 008/044 [abstract and poster 555] . Available at : http://www.retroconference.org/2003/Abstract/Abstract.aspx?AbstractID = 2075
   Google Scholar
• Murphy , R.L. , Sanne , I. , Cahn , P. , Phanupak , P. , Percival , L. Kelleher , T. 2003b . Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naïve subjects: 48-week results . AIDS , 17 : 2603 – 2614 .
   PubMed Web of Science ®Google Scholar
• Opravil , M. , Hirschel , B. , Lazzarin , A. , Furrer , H. , Chave , J.P. Yerly , S. 2002 . A randomized trial of simplified maintenance therapy with abacavir, lamivudine and zidovudine in human immunodeficiency virus infection . Journal of Infectious Diseases , 185 : 1251 – 1260 .
   PubMed Web of Science ®Google Scholar
• Panel on Clinical Practices for Treatment of HIV Infection (2004) . Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [updated 23 March 2004] . Available at: http://aidsinfo.nih.gov/guidelines/adult/AA_032304.pdf
   Google Scholar
• Périard , D. , Telenti , A. , Sudre , P. , Cheseaux , J.J. , Halfon , P. , Reymond , M.J. , et al. for the Swiss HIV Cohort Study (1999) . Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors . Circulation , 100 , 700 – 705 .
   PubMed Web of Science ®Google Scholar
• Piscitelli , S.C. and Gallicano , K.D. 2001 . Interactions among drugs for HIV and opportunistic infections . New England Journal of Medicine , 344 : 984 – 996 .
   PubMed Web of Science ®Google Scholar
• Purnell , J.Q. , Zambon , A. , Knopp , R.H. , Pizzuti , D.J. , Achari , R. Leonard , J.M. 2000 . Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects . AIDS , 14 : 51 – 57 .
   PubMed Web of Science ®Google Scholar
• Rickerts , V. , Brodt , H.R. , Staszewski , S. and Stille , W. 2000 . Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: The Frankfurt HIV-cohort study . European Journal of Medical Research , 5 : 329 – 333 .
   PubMedGoogle Scholar
• Riddler , S.A. , Smit , E. , Cole , S.R. , Li , R. , Chmiel , J.S. Dobs , A. 2003 . Impact of HIV infection and HAART on serum lipids in men . Journal of the American Medical Association , 289 : 2978 – 2982 .
   PubMed Web of Science ®Google Scholar
• Ruiz , L. , Negredo , E. , Domingo , P. , Paredes , R. , Francia , E. Balague , M. 2001 . Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: One-year prospective follow-up of a multicenter, randomized, controlled study . Journal of Acquired Immune Deficiency Syndrome , 27 : 229 – 236 .
   PubMed Web of Science ®Google Scholar
• Saag , M.S. , Powderly , W.G. , Schambelan , M. , Benson , C.A. , Carr , A. Cirrier , J.S. 2002 . Switching antiretroviral drugs for treatment of metabolic complications in HIV-1 infection: Summary of selected trials . Topics in HIV Medicine , 10 : 47 – 51 .
   Google Scholar
• Sanne , I. , Piliero , P. , Squires , K. , Thiry , A. , & Schnittman , S. , for the AI424-007 Clinical Trial Group (2003) . Results of a phase 2 clinical trial at 48 weeks (AI424-007): A dose-ranging safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naïve subjects . Journal of Acquired Immune Deficiency Syndrome , 32 , 18 – 29 .
   PubMed Web of Science ®Google Scholar
• Schaefer , E.J. , McNamara , J.R. , Genest , J. Jr and Ordovas , J.M. 1988 . Clinical significance of hypertriglyceridemia . Seminars in Thrombosis and Hemostasis , 14 : 143 – 148 .
   PubMed Web of Science ®Google Scholar
• Schambelan , M. , Benson , C.A. , Carr , A. , Cirrier , J.S. , Dubé , M.P. Gerber , J.G. 2002 . Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: Recommendations of an International AIDS Society—USA panel . Journal of Acquired Immune Deficiency Syndrome , 31 : 257 – 275 .
   PubMed Web of Science ®Google Scholar
• Shor-Posner , G. , Basit , A. , Lu , Y. , Cabrejos , C. , Chang , J. Fletcher , M. 1993 . Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection . American Journal of Medicine , 94 : 515 – 520 .
   PubMed Web of Science ®Google Scholar
• Staszewski , S. , Gallant , J.E. , Pozniak , A.L. , Suleiman , J.M.A.H. , Dejesus , E. , Lu , B. , et al. (2003) . Favorable metabolic profile for tenofovir disoproxil fumarate (TDF) versus stavudine (d4T) when used in combination with lamivudine and efavirenz in antiretroviral naïve patients: 96-week interim results [abstract 562]. 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, France .
   Google Scholar
• Tobert , J.A. 1988 . Efficacy and long-term adverse effect pattern of lovastatin . American Journal of Cardiology , 62 : 28J – 34J .
   PubMed Web of Science ®Google Scholar
• Transon , C. , Leemann , T. and Dayer , P. 1996 . In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors . European Journal of Clinical Pharmacology , 50 : 209 – 215 .
   PubMed Web of Science ®Google Scholar
• Van der Valk , M. , Kastelein , J.J. , Murphy , R.L. , Van Leth , F. , Katlama , C. , Horban , A. , et al. , on behalf of the Atlantic Study Team (2001) . Nevirapine-containing antiretroviral therapy in HIV-1 infected patients' results in an anti-atherogenic lipid profile . AIDS , 15 , 2407 – 2414 .
   PubMed Web of Science ®Google Scholar
• Van Leth , F. , Phanuphak , P. , Gazzard , B. , Cahn , P. , Wood , R. , Bloch , M. , et al. , (2003) . Lipid changes in a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine (2NN Study) [abstract 97] . Available at: http://www.retroconference.org/2003/Abstract/Abstract.aspx?AbstractID = 97
   Google Scholar
• Voorman , R.L. , Maio , S.M. , Hauer , M.J. , Sanders , P.E. , Payne , N.A. and Ackland , M.J. 1998 . Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: Probable involvement of CYP2D6 and CYP3A . Drug Metabolism and Disposition , 26 : 631 – 639 .
   PubMed Web of Science ®Google Scholar
• Walli , R. , Michl , G.M. , Bogner , J.R. and Goebel , F.D. 2001 . Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir . European Journal of Medical Research , 6 : 413 – 421 .
   PubMed Web of Science ®Google Scholar
• Williams , D. and Feely , J. 2002 . Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors . Clinical Pharmacokinetics , 41 : 343 – 370 .
   PubMed Web of Science ®Google Scholar
• Zangerle , R. , Sarcletti , M. , Gallati , H. , Reibnegger , G. , Wachter , H. and Fuchs , D. 1994 . Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation . Journal of Acquired Immune Deficiency Syndrome , 7 : 1149 – 1156 .
   PubMed Web of Science ®Google Scholar